{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:44Z","timestamp":1761870944559,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.clml.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T19:15:49Z","timestamp":1487272549000},"page":"320-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia"],"prefix":"10.1016","volume":"17","author":[{"given":"Amal S.","family":"Alabdulwahab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein G.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Sherisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa M.","family":"Elbjeirami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Alieldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.02.008_bib1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcome for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols: a comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.008_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric inspired therapy in adults with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRAALL 2003 study","volume":"27","author":"Huget","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.008_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukemia with a modified pediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.008_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.23149","article-title":"Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric inspired regimens: systematic review and meta-analysis","volume":"87","author":"Ram","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.008_bib5","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2014-11-551481","article-title":"How I treat acute lymphoblastic leukemia in older adolescents and young adult","volume":"125","author":"Curran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.008_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.24285","article-title":"Pediatric inspired therapy compared to allografting for Philadelphia chromosome negative adult ALL in first complete remission","volume":"91","author":"Seftel","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.008_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcome for older adolescents and young adults (AYA) with acute lymphoblastic leukemia: early results of US Intergroup Trial C10403","volume":"124","author":"Stock","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.008_bib8","doi-asserted-by":"crossref","first-page":"1510a","DOI":"10.1182\/blood.V118.21.1510.1510","article-title":"Treatment toxicity in adolescents and young adults (AYA) patients compared with younger patients treated for high risk B precursor acute lymphoblastic leukemia (HR-ALL): a report from\u00a0Children's Oncology Group (COG) study AALL032","volume":"118","author":"Larsen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.008_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V126.23.80.80","article-title":"A\u00a0multicenter phase II study using a dose intensified pegylated-asparginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCP ALL Consortium trial","volume":"126","author":"DeAngelo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.008_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.008_bib11","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.3747\/co.23.3077","article-title":"Venous thromboembolism prevention during asparaginase- based therapy for acute lymphoblastic leukemia","volume":"23","author":"Sibai","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2017.02.008_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood.V126.23.248.248","article-title":"Higher incidence of treatment-related toxicities in non-Hispanic patients undergoing therapy for newly diagnosed pediatric acute lymphoblastic leukemia on Dana Farber Cancer Institute ALL Consortium protocol 05-001","volume":"126","author":"Kahn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.008_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood.V126.23.250.250","article-title":"Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia","volume":"126","author":"Karol","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.008_bib14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/pbc.24420","article-title":"Children Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia","volume":"60","author":"Hunger","year":"2013","journal-title":"Pediatr Blood Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016305560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016305560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:57Z","timestamp":1761870537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016305560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2152265016305560"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}